Carl Tilbury

Carl Tilbury has a diverse work experience that spans various industries and roles. Carl began their career at ExxonMobil as a Summer Intern in 2011. From there, they joined AbbVie as a Graduate Intern in Solid State Chemistry, where they developed a computational screening model for crystal hydrate formation for pipeline drug compounds.

In 2012, Carl joined the University of California, Santa Barbara as a Graduate Researcher. During their time there, they focused on developing mechanistic models to predict crystal growth shapes accurately, specifically for pharmaceutical process development. Carl successfully secured significant funding from NSF and major pharma companies, published multiple articles, and presented at conferences. Additionally, they mentored postdocs and master's students.

After their research role, Carl transitioned to consulting at the Boston Consulting Group (BCG). Carl worked as a Consultant and later advanced to the role of Project Leader. At BCG, they gained expertise in strategic and project management, working with various clients.

In 2021, Carl joined BrightInsight as the Director of Digital Innovation and Strategy. In this role, they led the development of the company's digital product innovation consulting and value engineering function. Additionally, they served as the Head of Strategic Partnerships, responsible for screening and negotiating with existing and potential partners across different areas of the organization. Carl also led corporate development activities and played a pivotal role in shaping the company's product and go-to-market strategies.

Most recently, in 2023, Carl joined Genesis Therapeutics as the Senior Director of Business Development and Strategy.

Carl Tilbury completed their education in a chronological manner. From 2008 to 2012, they attended the University of Cambridge, where they obtained a Master of Engineering (MEng) and a Bachelor of Arts (BA) in Chemical Engineering. Additionally, in 2009-2010, they participated in a Cambridge-MIT Exchange program at the Massachusetts Institute of Technology, focusing on Chemical Engineering. Afterwards, from 2012 to 2017, they pursued their Doctor of Philosophy (PhD) degree at UC Santa Barbara, further specializing in Chemical Engineering.